Strategies for Managing Radiation-Induced Mucositis in Head and Neck Cancer

Seminars in Radiation Oncology

Volumn 19, Issue 1, 2009, Pages 29-34

  Rosenthal, David I ^a   Trotti, Andrea ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMIFOSTINE; AMPHOTERICIN B; ANALGESIC AGENT; BENZYDAMINE; BETAMETHASONE; CETUXIMAB; CISPLATIN; FENTANYL; FLUCONAZOLE; FLUOROURACIL; GLUTAMINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ISEGANAN; KETOCONAZOLE; LIDOCAINE; MISOPROSTOL; PALIFERMIN; PLACEBO; POLYMYXIN B; PREDNISOLONE; PROSTAGLANDIN E2; RK 0202; SAFORIS; SUCRALFATE; TOBRAMYCIN; UNCLASSIFIED DRUG;

CANDIDIASIS; CLINICAL TRIAL; DEVICE; DYSPHAGIA; HEAD AND NECK CANCER; HUMAN; LOW LEVEL LASER THERAPY; MOUTH DISEASE; MOUTH HYGIENE; MOUTH INFECTION; MOUTHWASH; MUCOSA INFLAMMATION; NAUSEA; ORAL MUCOSITIS; PAIN; PHARYNGITIS; PRIORITY JOURNAL; RADIATION; REVIEW; RISK FACTOR; SYMPTOM; THROAT DISEASE;

ACETYLCYSTEINE; AMIFOSTINE; CARCINOMA, SQUAMOUS CELL; GLUTAMINE; HEAD AND NECK NEOPLASMS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LASER THERAPY, LOW-LEVEL; MOUTHWASHES; ORAL HYGIENE; PAIN; RISK FACTORS; STOMATITIS;

EID: 56349149990     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2008.09.006     Document Type: Review

References (57)

1. Sonis T., Peterson D.E., McGuire D.B., et al. Prevention of mucositis in cancer patients. J Natl Cancer Inst Monogr 29 (2001) 1-2
2. Rosenthal C., Karthaus M., and Ganser A. New strategies in the treatment and prophylaxis of chemo- and radiotherapy-induced oral mucositis. Antibiot Chemother 50 (2000) 115-132
3. Rosenthal D.I., Lewin J.S., and Eisbruch A. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 24 (2006) 2636-2643
4. Rosenthal D.I., Mendoza T.R., Chambers M.S., et al. Measuring head and neck cancer symptom burden: The development and validation of the M.D. Anderson symptom inventory, head and neck module. Head Neck 29 (2007) 923-931
5. Rosenthal D.I., Mendoza T.R., Chambers M.S., et al. The M.D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis. Int J Radiat Oncol Biol Phys (2008) May 21; [Epub ahead of print]
6. Jones H.A., Hershock D., Machtay M., et al. Preliminary investigation of symptom distress in the head and neck patient population: Validation of a measurement instrument. Am J Clin Oncol 29 (2006) 158-162
7. Bjordal K., Kaasa S., and Mastekaasa A. Quality of life in patients treated for head and neck cancer: A follow-up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys 28 (1994) 847-856
8. Cooper J.S., Fu K., Marks J., et al. Late effects of radiation therapy in the head and neck region. Int J Radiat Oncol Biol Phys 31 (1995) 1141-1164
9. Harrison L.B., Zelefsky M.J., Pfister D.G., et al. Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck 19 (1997) 169-175
10. Epstein J.B., Gorsky M., Guglietta A., et al. The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer 89 (2000) 2258-2265
11. Kagami H., Hiramatsu Y., Hishida S., et al. Salivary growth factors in health and disease. Adv Dent Res 14 (2000) 99-102
12. Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res 66 (1987) 648-653
13. Sonis S.T. Is oral mucositis an inevitable consequence of intensive therapy for hematologic cancers?. Nat Clin Pract Oncol 2 (2005) 134-135
14. Blijlevens N.M. Implications of treatment-induced mucosal barrier injury. Curr Opin Oncol 17 (2005) 605-610
15. Sonis S.T. The pathobiology of mucositis. Nat Rev Cancer 4 (2004) 277-284
16. Bensinger W., Schubert M., Ang K.K., et al. NCCN Task Force Report. Prevention and management of mucositis in cancer care. J Natl Compr Canc Netw 6 suppl 1 (2008) S1-S21
17. Quinn B., Potting C.M., Stone R., et al. Guidelines for the assessment of oral mucositis in adult chemotherapy, radiotherapy and haematopoietic stem cell transplant patients. Eur J Cancer 44 (2008) 61-72
18. Keefe D.M., Schubert M.M., Elting L.S., et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109 (2007) 820-831
19. Worthington H.V., and Clarkson J.E. Eden OB: Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 4 (2007) CD000978
20. Garden A.S., Asper J.A., Morrison W.H., et al. Is concurrent chemoradiation the treatment of choice for all patients with stage III or IV head and neck carcinoma?. Cancer 100 (2004) 1171-1178
21. Garden A.S., Morrison W.H., Wong P.F., et al. Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 67 (2007) 438-444
22. Rosenthal D.I., and Blanco A.I. Head and neck squamous cell carcinoma: Optimizing the therapeutic index. Expert Rev Anticancer Ther 5 (2005) 501-514
23. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 (2003) 92-98
24. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
25. National Cancer Institute: Oral Complications of Chemotherapy and Head/Neck Radiation (PDQ). http://www.cancer.gov/cancer topics/pdg/supportivecare/oralcomplications Accessed Oct. 9, 2008
26. Sonis S.T., Elting L.S., Keefe D., et al. Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100 (2004) 1995-2025
27. Marx R.E., and Johnson R.P. Studies in the radiobiology of osteoradionecrosis and their clinical significance. Oral Surg Oral Med Oral Pathol 64 (1987) 379-390
28. Rosenthal D.I., Chambers M.S., Fuller C.D., et al. Beam path toxicities to non-target structures during intensity modualted radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 72 (2008) 747-755
29. McGuire D.B., Correa M.E., Johnson J., et al. The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer 14 (2006) 541-547
30. Barasch A., Spijkervet A., Garden A., et al. Efficacy of opioid analgesics and effect on functional status of pain caused by radiation-induced mucositis among patients with head and neck cancer. J Clin Oncol 26 (2008) abstr 6019
31. Eisbruch A., Levendag P.C., Feng F.Y., et al. Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer?. The Michigan and Rotterdam experiences. Int J Radiat Oncol Biol Phys 69 (2007) S40-S42
32. Feng F.Y., Kim H.M., Lyden T.H., et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: Early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 68 (2007) 1289-1298
33. Chao K.S., Majhail N., Huang C.J., et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: A comparison with conventional techniques. Radiother Oncol 61 (2001) 275-280
34. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18 (2000) 3339-3345
35. Chambers M.S., Welsh D.V., Scrimger R.A., et al. RK-0202 for radiation-induced oral mucositis. J Clin Oncol 24 (2006) 5523
36. Ryu J.K., Swann S., LeVeque F., et al. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: A double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. Int J Radiat Oncol Biol Phys 67 (2007) 643-650
37. Nicolatou O., Sotiropoulou-Lontou A., Skarlatos J., et al. A pilot study of the effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients during X-radiation therapy: A preliminary report. Int J Radiat Oncol Biol Phys 42 (1998) 551-556
38. Rovirosa A., Ferre J., and Biete A. Granulocyte macrophage-colony-stimulating factor mouthwashes heal oral ulcers during head and neck radiotherapy. Int J Radiat Oncol Biol Phys 41 (1998) 747-754
39. Sprinzl G.M., Galvan O., de Vries A., et al. Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis. Eur J Cancer 37 (2001) 2003-2009
40. Staar S., Rudat V., Stuetzer H., et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-Results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50 (2001) 1161-1171
41. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
42. Henke M., Mattern D., Pepe M., et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol 24 (2006) 4708-4713
43. Spielberger R., Stiff P., Bensinger W., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351 (2004) 2590-2598
44. Brizel D.M., Murphy B.A., Rosenthal D.I., et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 26 (2008) 2489-2496
45. Antunes H.S., de Azevedo A.M., da Silva Bouzas L.F., et al. Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: A randomized trial. Blood 109 (2007) 2250-2255
46. Schubert M.M., Eduardo F.P., Guthrie K.A., et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer 15 (2007) 1145-1154
47. Foote R.L., Loprinzi C.L., Frank A.R., et al. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol 12 (1994) 2630-2633
48. Symonds R.P., McIlroy P., Khorrami J., et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: A placebo-controlled double-blind trial. Br J Cancer 74 (1996) 312-317
49. Trotti A., Garden A., Warde P., et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 58 (2004) 674-681
50. Leborgne J.H., Leborgne F., Zubizarreta E., et al. Corticosteroids and radiation mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial. Radiother Oncol 47 (1998) 145-148
51. Hanson W.R., Marks J.E., Reddy S.P., et al. Protection from radiation-induced oral mucositis by a mouth rinse containing the prostaglandin E1 analog, misoprostol: A placebo controlled double blind clinical trial. Adv Exp Med Biol 400B (1997) 811-818
52. Porteder H., Rausch E., Kment G., et al. Local prostaglandin E2 in patients with oral malignancies undergoing chemo- and radiotherapy. J Craniomaxillofac Surg 16 (1988) 371-374
53. Labar B., Mrsic M., Pavletic Z., et al. Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 11 (1993) 379-382
54. Duenas-Gonzalez A., Sobrevilla-Calvo P., Frias-Mendivil M., et al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: A randomized double-blind study. Bone Marrow Transplant 17 (1996) 809-812
55. Lalla R.V., Schubert M.M., Bensadoun R.J., et al. Anti-inflammatory agents in the management of alimentary mucositis. Support Care Cancer 14 (2006) 558-565
56. Epstein J.B., Silverman Jr. S., Paggiarino D.A., et al. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: Results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92 (2001) 875-885
57. Epstein J.B., and Stevenson-Moore P. Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surg Oral Med Oral Pathol 62 (1986) 145-148